Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03509441 · ClinicalTrials.gov registry record

Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance

A clinical trial, sponsored by Stanford University.

Completed
Registry status
39
Enrollment target

NCT03509441: Completed study, sponsored by Stanford University.

NCT03509441 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03509441 has completed, sponsored by Stanford University.

COMPLETED
Registry status
39 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the relationship between insulin resistance (IR) and myocardial tissue abnormalities. The study will focus on a patient population, South Asians, with a high prevalence of IR.

Primary Outcome

The investigators will collect and store peripheral blood samples from every patient, identify those with high and low fibrosis levels using our described protocol, and then select patients with disproportionately high fibrosis levels given their disease burden. The investigators can test for the level of fibrosis by generating induced pluripotent stem cell-derived cardiomyocytes (iPSC- CMs) from these collected blood samples. These iPSC-CMs will be tested, in vitro, for drug sensitivity, susce

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2015-01-15
Est. Completion 2019-11-11
Stanford University

1,744 total trials

What the finished NCT03509441 record still lists

NCT03509441 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT03509441 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03509441 about?

NCT03509441 is a clinical study titled "Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance". The purpose of this study is to evaluate the relationship between insulin resistance (IR) and myocardial tissue abnormalities. The study will focus on a patient population, South Asians, with a high prevalence of IR.

What is the current status of trial NCT03509441?

This trial is currently completed. The enrollment target is 39 participants. The study started on 2015-01-15. Estimated completion is 2019-11-11.

Who is sponsoring clinical trial NCT03509441?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03509441, the US trial registry maintained by the National Library of Medicine. NCT03509441 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.